Another limitation of our work was that some patients who were on antiplatelet agents, such as aspirin or clopidogrel, within 2–8 days preoperatively may have been included. These data are unavailable and could potentially affect the results, as these agents are known to affect clot strength.23 Again, future studies shall determine the effects of protamine on TEG tracing in patients not taking antiplatelet agents.
1 DeLaria GA, Tyner JJ, Hayes CL, Armstrong BW. Heparin
mismatch. A controllable factor in bleeding after open heart surgery. Arch Surg 1994; 129:944–950, discussion 950–941.
2 McLaughlin KE, Dunning J. In patients post cardiac surgery
do high doses of protamine
cause increased bleeding? Interact Cardiovasc Thorac Surg 2003; 2:424–426.
3 Miyashita T, Nakajima T, Hayashi Y, Kuro M. Hemostatic effects of low-dose protamine
following cardiopulmonary bypass. Am J Hematol 2000; 64:112–115.
4 Kamath BSK, Fozard JR. Control of heparinisation during cardiopulmonary bypass. Anaesthesia
5 Mattox KL, Guinn GA, Rubio PA, Beall AC Jr. Use of the activated coagulation time in intraoperative heparin
reversal for cardiopulmonary operations. Ann Thorac Surg 1975; 19:634–638.
6 Spiess BD, Tuman KJ, McCarthy RJ, et al
. Thromboelastography as an indicator of postcardiopulmonary bypass coagulopathies. J Clin Monit 1987; 3:25–30.
7 Murray DJ, Brosnahan WJ, Pennell B, et al
detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin
assays. J Cardiothorac Vasc Anesth 1997; 11:24–28.
8 Hashimoto K, Sasaki T, Hachiya T, et al
. Real time measurement of heparin
concentration during cardiopulmonary bypass. J Cardiovasc Surg (Torino) 1999; 40:645–651.
9 Aziz KAA, Masood O, Hoschtitzky JA, Ronald A. Does use of the Hepcon(R) point-of-care coagulation monitor to optimise heparin
dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery
? Interact Cardiovasc Thorac Surg 2006; 5:469–482.
10 Shih RL, Cherng YG, Chao A, et al
. Prediction of bleeding diathesis in patients undergoing cardiopulmonary bypass during cardiac surgery
: viscoelastic measures versus routine coagulation test. Acta Anaesthesiol Sin 1997; 35:133–139.
11 Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995; 9:168–173.
12 Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin
therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin
dosage. J Thorac Cardiovasc Surg 1975; 69:685–689.
13 Pifarre R, Babka R, Sullivan HJ, et al
. Management of postoperative heparin
rebound following cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981; 81:378–381.
14 Cohen JA, Frederickson EL, Kaplan JA. Plasma heparin
activity and antagonism during cardiopulmonary bypass with hypothermia. Anesth Analg 1977; 56:564–570.
15 Despotis GJ, Joist JH, Hogue CW Jr, et al
. The impact of heparin
concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995; 110:46–54.
16 Shigeta O, Kojima H, Hiramatsu Y, et al
. Low-dose protamine
based on heparin
titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999; 118:354–360.
17 Nielsen VG. Protamine
enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg 2006; 81:1720–1727.
18 Mochizuki T, Olson PJ, Szlam F, et al
reversal of heparin
affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87:781–785.
19 Ammar T, Fisher CF. The effects of heparinase 1 and protamine
on platelet reactivity. Anesthesiology 1997; 86:1382–1386.
20 Griffin MJ, Rinder HM, Smith BR, et al
. The effects of heparin
, and heparin
reversal on platelet function under conditions of arterial shear stress. Anesth Analg 2001; 93:20–27.
21 Shanberge JN, Murato M, Quattrociocchi-Longe T, van Neste L. Heparin
complexes in the production of heparin
rebound and other complications of extracorporeal bypass procedures. Am J Clin Pathol 1987; 87:210–217.
22 Nielsen VG. Effects of aprotinin on plasma coagulation kinetics determined by thrombelastography: role of factor XI. Acta Anaesthesiol Scand 2006; 50:168–172.
23 Swallow RA, Agarwala RA, Dawkins KD, Curzen NP. Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy? Platelets 2006; 17:385–392.